Introduction
============

Acute lymphocytic leukemia (ALL) is the most prevalent type of cancer in childhood.[@b1-vhrm-11-479] As an increasing number of cancer survivors reaches adulthood, there may be consequences of the treatment, especially adiposity and components of the metabolic syndrome (MS), which predispose to cardiovascular disease (CVD) and enhance mortality.[@b2-vhrm-11-479]--[@b10-vhrm-11-479] According to the recommendations of the American Association of Cardiology in collaboration with the Council for Cardiovascular Disease in the Young,[@b3-vhrm-11-479] based on the pediatric conditions and their risk of CVD, patients treated for childhood cancer should be classified as tier III, which means the presence of clinical criteria for MS and increased epidemiological risk of premature CVD.[@b2-vhrm-11-479]--[@b10-vhrm-11-479]

The pathophysiology of atherosclerosis involves many factors, such as endothelial dysfunction and chronic inflammation of the arteries.[@b11-vhrm-11-479],[@b12-vhrm-11-479] Insulin resistance (IR), hyperinsulinemia, and increased fatty free acids are considered the initial mechanisms of endothelial dysfunction, which progress to atherosclerosis,[@b12-vhrm-11-479],[@b13-vhrm-11-479] being worsened by other aspects, such as dyslipidemia, smoking, diabetes mellitus, and hypertension.[@b11-vhrm-11-479],[@b12-vhrm-11-479] Subclinical atherosclerosis may be detected by the increment of carotid intima-media thickness (cIMT), a simple and noninvasive method, which encompasses an intermediate marker of CVD.[@b14-vhrm-11-479]--[@b18-vhrm-11-479]

Adipokines, comprising adiponectin, leptin, resistin, cytokines, and monocyte chemoattractant protein-1 (MCP-1), are also associated with endothelial dysfunction and atherogenesis. Adiponectin, as well as leptin-to-adiponectin ratio, is related to cIMT, and is considered a reliable indicator for atherosclerosis.[@b19-vhrm-11-479],[@b20-vhrm-11-479] In addition, the upregulation of endothelial cell MCP-1 production by low-density lipoprotein (LDL) oxidation is considered a major initiating event in atherogenesis.[@b21-vhrm-11-479]

In cancer survivors, the risk factors for vascular structural and functional modifications include those related to the patient, disease, or treatment, especially chemotherapy and cranial radiation therapy (CRT) and/or cervical radiation therapy, but also hormonal deficiencies and the association with the components of the MS.[@b4-vhrm-11-479],[@b14-vhrm-11-479]--[@b18-vhrm-11-479]

Nonetheless, there are few studies as regards the relationship between ALL, the exposure to CRT, the components of the MS, and the endothelium structure,[@b2-vhrm-11-479],[@b8-vhrm-11-479] and there is no study evaluating the adipokines in this context. Thus, the aim of this study was to evaluate the effect of body composition, metabolic profile, and adipokines on cIMT in young survivors of childhood ALL.

Materials and methods
=====================

Study population
----------------

This was a comparative cross-sectional study of a randomly selected sampling of ALL survivors of both sexes from the Pediatric Oncology Institute (Federal University of Sao Paulo, Brazil), admitted from May 1991 to June 2003, and a leukemia-free control group. The study was approved by the Ethics Research Committee of Federal University of Sao Paulo (Number 1197/07). To participate in this study, patients or parents, when appropriate, signed an informed consent form.

ALL subjects completed the Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia (GBTLI) international protocol. Details comprising drugs and CRT can be read elsewhere.[@b22-vhrm-11-479],[@b23-vhrm-11-479] CRT was applied prophylactically to those at high risk of relapse, defined according to the recommendations of the GBTLI, and/or therapeutically to those with central nervous system involvement, defined as blast cells greater than 5% in cerebrospinal fluid.[@b22-vhrm-11-479],[@b23-vhrm-11-479]

The inclusion criteria comprised the following: chronological age between 15 years and 24 years; the complete clinical remission of ALL (complete absence of the disease in bone marrow and blood); no ALL therapy for at least 2 years; complete pubertal development (menarche in girls and Tanner stage IV or above in boys);[@b24-vhrm-11-479],[@b25-vhrm-11-479] growth of less than 1 cm/year; bone age with full epiphyseal plate fusion; normal renal, thyroid, gonadal, and adrenal profiles (spontaneous or under hormonal replacement therapy); and insulin-like growth factor-1 (IGF-1) within the normal range. The following were excluded from the study: patients who used anorexigens, insulin-sensitivity medications, or other drugs that interfere with adiposity (eg, metformin, sibutramine, and fluoxetine); those who had experienced exogenous growth hormone (GH) administration within 2 years prior to study enrollment or a bone marrow transplantation; and those who were pregnant, were postpartum, or had Down's syndrome.

Survivors were stratified into two groups according to the exposure to CRT (irradiated and nonirradiated). Characteristics of host/disease and therapy were assessed from clinical examinations and/or medical records, encompassing sex, age at ALL diagnosis, age at assessment, age at the time of receiving and dose of CRT (if employed), time post-therapy, medications, or eventful past medical history.

The control group was selected among peers and/or relatives of the ALL patients, and was composed of healthy, leukemia-free subjects of similar age and body mass index (BMI), who did not use any medication.

Variables
---------

All the variables were determined for both ALL patients (irradiated or not) and the control group.

### Adiposity indexes

Adiposity indexes comprised body composition and fat distribution variables. Body composition encompassed BMI and fat mass index (FMI). BMI was calculated as the weight in kilograms divided by height in meters squared, and converted to *Z* scores based on the National Center for Health Statistics 2000 Centers for Disease Control and Prevention growth charts.[@b26-vhrm-11-479] The FMI was calculated as the fat mass (in kilograms) divided by height in meters squared (kg/m^2^), body fat mass being assessed by dual-energy X-ray absorptiometry, Hologic Discovery 4500 (QDR-4500A; Hologic Inc., Bedford, MA, USA).

Fat distribution indexes comprised computed tomography (CT) scan-derived abdominal adipose tissue, encompassing visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT), both measured according to the method described elsewhere.[@b6-vhrm-11-479],[@b9-vhrm-11-479]

### Blood pressure, metabolic profile, and growth factor

Systolic blood pressure (BP) and diastolic BP (in mmHg) were both measured with the patient in the sitting position after 5 minutes of rest in a tranquil environment, by auscultation, at an average of three outlets in the right arm (Tycos^®^ Welch Allyn, NY, USA).

Metabolic profile included LDL cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (enzymatic colorimetric method, in mmol/L). Glucose values (method: automated) and insulin (method: ACTIVE^®^ Insulin ELISA DSL-10-1600; Diagnostics Systems Laboratories, Inc., Webster, TX, USA) were used to calculate the homeostasis model assessment -- insulin resistance (HOMA1-IR).[@b27-vhrm-11-479]

IGF-1 (in nmol/L) was analyzed by a sandwich assay, one-step chemiluminescence using coated magnetic microparticles (LIAISON^®^ IGF-1 OS-313, 231; Gruppe Biomedica, Inc., Vienna, Austria), whose intra-assay coefficient of variability (CV) and inter-assay CV were, respectively, 3.7% and 4.6%, with minimum detection limit of 3.0 ng/mL and 100% of specificity.

### Adipokines

1.  Leptin-to-adiponectin ratio (ng/µg): leptin (in ng/mL) being analyzed by "Dual Range" enzyme-linked immunosorbent assay (ELISA) (Linco Research, Inc., St Charles, MO, USA; catalog number EZHL-80SK) with intra-assay CV of 3.6%, inter-assay CV of 4.0%, minimum detection limit of 0.5 ng/mL, and specificity of 100%, and adiponectin (in µg/mL) being evaluated by ELISA (R&D Systems, Inc., Minneapolis, MN, USA; catalog number DY1065) with intra-assay CV of 6.2%, inter-assay CV of 7.2%, minimum detection limit of 0.1 ng/mL, and specificity of 100%.

2.  MCP-1 (in pg/mL): ELISA (R&D Systems, Inc.; catalog number DY279) with intra-assay CV below 10%, inter-assay CV below 15%, minimum detection limit of 10 pg/mL, and specificity of 100%.

### Carotid intima-media thickness

cIMT was measured in the supine position, 1.0 cm below the carotid bulb of right and left common carotid arteries (Sonos 5500, Hewlett Packard^®^), coupled to a high-resolution linear transducer with frequency up to 11 MHz, and image acquisition was performed in the longitudinal plane in two-dimensional mode, with simultaneous cardiac monitoring, by one of two experienced observers, whose intraobserver variation was 0.05±0.02 mm and interobserver variation was 0.07±0.04 mm. The measurement was performed in the anterior or posterior wall of the artery, in the distance between two lines represented by the echogenic interfaces lumen-intima and media-adventitia of carotid wall. For each side (right and left), the result was calculated by the average of the measurements of three consecutive cardiac cycles, taking into consideration the R wave peak.[@b28-vhrm-11-479] Subsequently, the mean measurement of both sides was used for further analyses: (right cIMT + left cIMT)/2.

Statistical analysis
--------------------

Statistical analysis was initially made in a descriptive way through some summary measures such as mean, median, minimum and maximum values, standard deviation (SD), and absolute and relative frequencies (percentage). The inferential analyses were the following: As regards exposure to CRT/group (nonirradiated ALL patients vs irradiated ALL patients vs control subjects): Kruskal--Wallis test, with Bonferroni--Dunn post hoc test for pairwise comparisons if statistically significant, in the comparison of age at assessment (years), BMI (*Z* score), VAT (cm^3^), SAT (cm^3^), HOMA1-IR, triglycerides (mmol/L), systolic and diastolic BP (mmHg), IGF-1 (nmol/L), leptin-to-adiponectin ratio (ng/µg), MCP-1 (pg/mL), and cIMT (mm); one-way analysis of variance, with Duncan post hoc test for pairwise comparisons if statistically significant, in the comparison of FMI (kg/m^2^), LDL-C (mmol/L), and HDL-C (mmol/L); and Student's *t*-test for independent samples in the comparison of time post-therapy (years) between ALL subjects.As regards sex of ALL patients: Mann--Whitney test in the comparison of age at assessment (years), BMI (*Z* score), FMI (kg/m^2^), VAT (cm^3^), SAT (cm^3^), HOMA1-IR, triglycerides (mmol/L), diastolic BP (mmHg), IGF-1 (nmol/L), leptin-to-adiponectin ratio (ng/µg), MCP-1 (pg/mL), and cIMT (mm); and Student's *t*-test for independent samples in the comparison of time post-therapy (years), LDL-C (mmol/L), HDL-C (mmol/L), and systolic BP (mmHg).As regards sex of the control group: Mann--Whitney test in the comparison of FMI (kg/m^2^), VAT (cm^3^), SAT (cm^3^), HOMA1-IR, triglycerides (mmol/L), systolic BP (mmHg), and cIMT (mm); and Student's *t*-test for independent samples in the comparison of age at assessment (years), BMI (*Z* score), LDL-C (mmol/L), HDL-C (mmol/L), diastolic BP (mmHg), IGF-1 (nmol/L), leptin-to-adiponectin ratio (ng/µg), and MCP-1 (pg/mL).Multiple linear regression analysis to study the relationship of cIMT (mm) according to the exposure to CRT, VAT (cm^3^), SAT (cm^3^), LDL-C (mmol/L), HDL-C (mmol/L), triglycerides (mmol/L), systolic and diastolic BP (mmHg), leptin-to-adiponectin ratio (ng/µg), and MCP-1 (pg/mL), among ALL subjects.To further explore the relation between VAT and SAT among ALL patients, the VAT-to-SAT ratio was determined, and the relationship between this ratio and cIMT was evaluated by Pearson's correlation.

Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS) version 19.0 for Windows and R version 2.15.2. In all tests, *P*\<0.050 was considered as statistically significant.

Results
=======

Subject's characteristics
-------------------------

The selected sample in this study consisted of 79 subjects, 55 being (69.6%) ALL patients, and 24 (30.4%), controls.

The age at assessment of the ALL patients was (given as mean with SD in parentheses) 18.6 (2.5) years, ranging from 15.0 years to 22.9 years, age at ALL diagnosis was 7.4 (3.9) years, and time post-therapy was 8.5 (3.5) years. Controls were 19.8 (3.1) years at study assessment, ranging from 14.3 years to 24.9 years. While compared to nonirradiated ALL subjects, controls were older (post hoc test, *P*=0.049) ([Table 1](#t1-vhrm-11-479){ref-type="table"}).

The ALL subjects were composed of 31 (56.4%) women and 24 (43.6%) men. The control group comprised 14 (58.3%) women and 10 (41.7%) men.

ALL subjects completed the GBTLI international protocol, and 25 (45.4%) ALL survivors received CRT with a dose of either 18 Gy (76%) or 24 Gy (24%) at a mean age of 8.0 (4.0) years. Three subjects also received alternative protocols to the GBTLI, which were employed due to medullar or testicular relapses but without complementary CRT. Among the irradiated survivors, one subject also received spinal irradiation, and two patients received testicular radiation therapy (24 Gy).

Body composition, fat distribution, and cIMT
--------------------------------------------

FMI was increased in female sex in both groups of patients, ALL subjects and controls (*P*\<0.050), and showed a trend toward an increase in ALL patients subjected to CRT (*P*=0.078). ([Table 1](#t1-vhrm-11-479){ref-type="table"} presents the comparison with regard to CRT exposure/group, and [Table 2](#t2-vhrm-11-479){ref-type="table"} presents further data as regards sex between ALL subjects.) Data regarding sex among controls are not shown.

VAT (post hoc test, *P*=0.018) and SAT (post hoc test, *P*=0.050) were increased among irradiated compared to non-irradiated ALL subjects, with no difference while compared to the controls. Concerning sex, no differences in VAT or SAT were detected in either ALL subjects or controls ([Tables 1](#t1-vhrm-11-479){ref-type="table"} and [2](#t2-vhrm-11-479){ref-type="table"}).

cIMT showed no difference as regards CRT exposure/group or sex, in both ALL subjects and controls ([Tables 1](#t1-vhrm-11-479){ref-type="table"} and [2](#t2-vhrm-11-479){ref-type="table"}).

Metabolic profile, adipokines, and BP
-------------------------------------

While analyzing data regarding the three groups ([Table 1](#t1-vhrm-11-479){ref-type="table"}), LDL-C was increased in both irradiated ALL patients and controls, when compared to nonirradiated ALL patients (post hoc test, *P*\<0.050), and MCP-1 was increased in controls (*P*=0.046), but no significant difference was determined in a post hoc test analysis.

When comparing sexes among ALL patients ([Table 2](#t2-vhrm-11-479){ref-type="table"}), HDL-C was decreased (*P*=0.006), while both systolic BP (*P*=0.028) and leptin-to-adiponectin ratio (*P*=0.011) were increased in ALL males.

There were no other statistically significant differences with respect to other characteristics measured and shown in [Table 1](#t1-vhrm-11-479){ref-type="table"} or [2](#t2-vhrm-11-479){ref-type="table"}, or regarding sex among the control group (data not shown).

Multiple linear regressions
---------------------------

This analysis was performed among ALL patients and showed that cIMT was positively related to the exposure to CRT (*P*=0.029), diastolic BP (*P*=0.016), and leptin-to-adiponectin ratio (*P*=0.048), while negatively related to SAT (*P*=0.007).

In the presence of exposure to CRT, SAT, diastolic BP and leptin-to-adiponectin ratio, VAT (*P*=0.437), LDL-C (*P*=0.252), HDL-C (*P*=0.411), triglycerides (*P*=0.390), systolic BP (*P*=0.977), and MCP-1 (*P*=0.741) did not influence cIMT. [Table 3](#t3-vhrm-11-479){ref-type="table"} presents model adjustment.

VAT-to-SAT ratio
----------------

cIMT and VAT-to-SAT ratio were positively correlated among ALL patients, as shown in [Figure 1](#f1-vhrm-11-479){ref-type="fig"} (*r*=0.355, *P*=0.008).

Discussion
==========

This study investigated the effect of fat distribution, lipid profile, BP, and adipokines on cIMT in young survivors of childhood ALL, and showed that even though CRT led to abdominal accumulation of fat and positively determined cIMT, a noninvasive assessment of subclinical atherosclerosis, SAT might represent a protective factor against adiposity-associated vascular disease.

The increase in cIMT in some groups of cancer survivors, particularly patients with brain tumors and Hodgkin's lymphoma, has been explained by a local effect of CRT and/or neck irradiation, which is dose-dependent, and influenced by other factors, such as chronological age, time since CRT, and association with components of the MS and GH insufficiency.[@b4-vhrm-11-479],[@b10-vhrm-11-479] An increase in cIMT has been observed in the group of patients who were treated with high doses of CRT (54 Gy) and/or cervical irradiation.[@b4-vhrm-11-479],[@b14-vhrm-11-479],[@b16-vhrm-11-479]--[@b18-vhrm-11-479],[@b29-vhrm-11-479]

In the present study, there was no significant difference in cIMT, taking into account CRT treatment or sexes. This finding is in accordance with previous studies concerning ALL survivors who received either low doses of CRT or no radiation, either adult long-term survivors or those who had just received their treatment, survivors who did not show any increase in carotid vascular measures, while compared to normal controls.[@b2-vhrm-11-479],[@b29-vhrm-11-479] It should be noted, however, that contrary to brain tumor survivors, patients treated for ALL receive less radiation overall and not specifically to the neck region. One of these studies in ALL survivors demonstrated only vascular dysfunction (but not increase in cIMT), as a marker of sub-clinical atherosclerosis, which was not evaluated in the present sample of ALL survivors so far.[@b29-vhrm-11-479] Conversely, the present sample of ALL survivors showed an increase in cIMT, while compared to patients selected from the Brazilian Metabolic Syndrome Study, matched by sex, chronological age, and BMI.[@b30-vhrm-11-479] Although age and sex are nonmodifiable elements that should be taken into account for vascular evaluation,[@b31-vhrm-11-479] to date, it is not possible to state that time off therapy, dose of CRT, sex, and chronological age have influenced the results in the present study, since patients were relatively young, evaluated with few time off therapy, and received low doses of CRT.[@b4-vhrm-11-479],[@b14-vhrm-11-479],[@b16-vhrm-11-479]--[@b18-vhrm-11-479],[@b29-vhrm-11-479],[@b31-vhrm-11-479]

CRT played a role in cIMT among this sample of young survivors of ALL, and might be considered a positive predictor of subclinical atherosclerosis, even though it is not possible to determine the critical dose of CRT associated with an increase in vascular structure so far. The exposure to CRT in ALL survivors caused a change in the distribution of fat, predominantly in the abdominal region, as previously documented in a study with this sample of ALL patients.[@b6-vhrm-11-479] Since the exact mechanism by which CRT modifies adipose tissue distribution is unknown, it is possible to declare that there was a relationship between the exposure to CRT and cIMT in this sample of ALL survivors. Excessive abdominal fat accumulation has been considered a frequent adverse effect in the period of the rebound of adiposity, and many years after therapy withdrawal in ALL survivors, particularly those exposed to CRT. CRT may affect energy regulatory pathways and the hypothalamic metabolic circuits resulting in body fat alterations. A hypo-thalamic insult, such as CRT or intrathecal methotrexate, may lead to modifications in satiety centers or increase parasympathetic tone. Moreover, GH deficiency, which might occur in ALL patients subjected to CRT, may have an impact on body composition and metabolic profile.[@b2-vhrm-11-479]--[@b6-vhrm-11-479],[@b9-vhrm-11-479],[@b32-vhrm-11-479]

SAT was a negative predictor of cIMT in this sample of young survivors of ALL, which concurs with previous statements that have evaluated the relationship between VAT and SAT.[@b33-vhrm-11-479],[@b34-vhrm-11-479] Furthermore, the VAT-to-SAT ratio also played a positive role in cIMT among ALL subjects. It appears that there is an interaction of SAT by modifying adverse effects of VAT, or the adverse effects of VAT might be lessened with increasing amounts of SAT. Nonetheless, SAT seems to display less insulin- and adrenergic-related lipolytic activity, to release fewer inflammatory adipokines and to have greater adiponectin expression, compared to VAT. The mechanisms that may underlie the potential beneficial effects of SAT in the presence of high amounts of VAT are not clear so far.[@b33-vhrm-11-479],[@b34-vhrm-11-479]

Diastolic BP showed a positive effect on cIMT in this sample of patients treated for ALL, but there was no relationship between cIMT and HOMA1-IR or lipid profile, which concurs with previous studies,[@b20-vhrm-11-479] even though factors associated with MS, such as HDL-C, LDL-C, and IR, potentially aggravate endothelial dysfunction and atherogenesis.[@b12-vhrm-11-479],[@b35-vhrm-11-479],[@b36-vhrm-11-479] In relation to hormonal deficiencies, especially GH deficiency, there were no statistical differences in IGF-1 levels while comparing groups, even though the group exposed to CRT showed lower levels, not clinically relevant and within the normal limits so far.

This study is the first to describe the relationship between cIMT, components of the MS, and adipokines in patients treated for ALL, either exposed or not to CRT. Leptin-to-adiponectin ratio, which reflects abdominal fat accumulation and is a biomarker of the MS, was associated with cIMT in this sample of young survivors of ALL, which has been previously described.[@b19-vhrm-11-479],[@b20-vhrm-11-479] Even though oxidized LDL-C may increase adherence and penetration of macrophages in the endothelial cell, this is a local event, and might explain why MCP-1 levels were not related to cIMT in this study.[@b21-vhrm-11-479]

This study included 55 survivors of ALL from a single institution, at a mean 8.5 years posttreatment, younger, at a shorter posttreatment interval compared to other studies, and none currently assessed within the period of the adiposity rebound, which features the 2 years after treatment withdrawal, in which there is an increment of the adiposity indexes.[@b2-vhrm-11-479],[@b5-vhrm-11-479],[@b8-vhrm-11-479],[@b9-vhrm-11-479],[@b32-vhrm-11-479],[@b37-vhrm-11-479] The sample size was small, and this may be considered a limitation of the study. It is noteworthy, however, that even though some of the characteristics of the control group (age, FMI, lipid profile, and adipokines) resemble those of the irradiated ALL patients, VAT and SAT were probably increased by CRT exposure, considering that this sample of ALL patients received intense medical support, overprotection due to illness, and parental caregiving, therefore reinforcing the deleterious effect of CRT on abdominal accumulation of fat among ALL survivors. Patients not subjected to CRT were younger than leukemia-free controls; however, this difference regarding age was not clinically relevant. ALL patients subjected to CRT may have undergone preceding GBTLI protocols (GBTLI-85 and GBTLI-93),[@b22-vhrm-11-479],[@b23-vhrm-11-479] which indicated prophylactic CRT to all patients at risk of relapse. Concerning CRT and its detrimental effects, the latest GBTLI-99 protocol has reserved therapeutic CRT entirely to patients with central nervous system involvement so that patients treated for ALL are not exposed to prophylactic CRT so far.[@b23-vhrm-11-479] Another aspect to be emphasized is that this study did not evaluate the endothelium function but only structural alterations of carotid wall. Moreover, there are no data concerning cIMT and/or adipokines before or during ALL therapy.

Conclusion
==========

In young survivors of childhood ALL, CRT modified the distribution of fat and was a positive predictor of cIMT. Leptin- to-adiponectin ratio, a biomarker of abdominal obesity and the MS, and diastolic BP also determined cIMT, a marker of subclinical atherosclerosis. Nonetheless, adiposity-associated vascular disease might be attenuated by SAT. Changes in body fat must be evaluated in this group of patients in the early course of survivorship in order to avoid premature CVD associated with atherosclerosis. Yet, further research as regards the possible protective effect of SAT on vascular disease is warranted.
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###### 

Summary measures of general characteristics, body composition and fat distribution, metabolic profile, blood pressure, and adipokine levels of ALL patients and controls

                                        Nonirradiated ALL patients   Irradiated ALL patients                                                                      Controls                                                                                                                                                                                                             
  ------------------------------------- ---------------------------- -------------------------------------------------------------------------------------------- ---------- ------- ------- ------- ---- -------------------------------------------------- ------- ------- --------- ------- ---- -------------------------------------------------- ------- ------- ------- ------- --------------------------------------------------
  Age at assessment (years)             30                           17.9[a](#tfn4-vhrm-11-479){ref-type="table-fn"}                                              17.3       15.0    22.9    2.6     25   19.4                                               19.9    15.0    22.8      2.3     24   19.8[a](#tfn4-vhrm-11-479){ref-type="table-fn"}    20.2    14.3    24.9    3.1     0.035[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  Time post-therapy (years)             30                           8.2                                                                                          8.6        2.5     14.9    3.5     25   9.0                                                8.0     2.6     16.4      3.4     --   --                                                 --      --      --      --      0.390[t](#tfn2-vhrm-11-479){ref-type="table-fn"}
  BMI (Z score)                         30                           −0.07                                                                                        0.30       −2.88   2.11    1.23    25   0.27                                               0.22    −2.44   2.14      1.12    24   0.54                                               0.42    −0.94   2.22    0.83    0.414[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  FMI (kg/m^2^)                         30                           5.8                                                                                          5.6        1.8     11.8    2.8     25   7.7                                                6.8     2.5     15.5      3.3     22   6.8                                                7.1     2.1     13.8    3.2     0.078[z](#tfn3-vhrm-11-479){ref-type="table-fn"}
  Visceral adipose tissue (cm^3^)       30                           89.7[b](#tfn5-vhrm-11-479){ref-type="table-fn"}                                              78.9       21.9    217.8   53.3    25   135.3[b](#tfn5-vhrm-11-479){ref-type="table-fn"}   127.5   47.3    265.3     68.7    24   116.8                                              104.7   33.6    255.3   53.4    0.016[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  Subcutaneous adipose tissue (cm^3^)   30                           283.8[c](#tfn6-vhrm-11-479){ref-type="table-fn"}                                             274.3      36.2    681.1   180.3   25   446.3[c](#tfn6-vhrm-11-479){ref-type="table-fn"}   359.5   38.3    1,077.4   261.2   24   402.5                                              398.9   71.1    893.6   208.4   0.029[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  HOMA1-IR                              30                           1.85                                                                                         1.53       0.82    4.74    0.94    25   2.20                                               2.00    0.71    4.75      1.16    24   1.60                                               1.26    0.71    4.05    0.86    0.098[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  LDL-C (mmol/L)                        30                           2.0[d](#tfn7-vhrm-11-479){ref-type="table-fn"},[e](#tfn8-vhrm-11-479){ref-type="table-fn"}   1.9        0.8     3.5     0.6     25   2.6[d](#tfn7-vhrm-11-479){ref-type="table-fn"}     2.6     1.2     4.1       0.7     24   2.5[e](#tfn8-vhrm-11-479){ref-type="table-fn"}     2.6     1.4     3.9     0.7     0.004[z](#tfn3-vhrm-11-479){ref-type="table-fn"}
  HDL-C (mmol/L)                        30                           1.2                                                                                          1.1        0.4     1.7     0.3     25   1.2                                                1.2     0.6     1.9       0.3     24   1.2                                                1.2     0.8     1.9     0.3     0.954[z](#tfn3-vhrm-11-479){ref-type="table-fn"}
  Triglycerides (mmol/L)                30                           0.9                                                                                          0.8        0.3     2.3     0.5     25   1.1                                                1.0     0.4     2.4       0.5     24   1.2                                                0.8     0.4     3.9     0.8     0.579[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  Systolic blood pressure (mmHg)        30                           110.7                                                                                        111.6      91.7    136.7   9.4     25   109.6                                              106.7   88.3    144.3     13.4    24   110.6                                              106.7   93.3    146.0   14.5    0.646[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  Diastolic blood pressure (mmHg)       30                           70.6                                                                                         70.0       58.3    100.0   8.3     25   70.3                                               70.0    56.7    100.0     9.3     24   66.4                                               66.7    46.7    81.7    8.6     0.251[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  IGF-1 (nmol/L)                        30                           45.7                                                                                         45.5       20.2    81.2    17.6    25   34.9                                               34.1    21.2    66.7      9.6     24   38.9                                               37.7    13.2    70.2    14.2    0.085[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  Leptin-to-adiponectin ratio (ng/µg)   30                           3.54                                                                                         2.72       1.21    9.11    2.26    25   3.07                                               2.76    1.16    6.89      1.46    23   2.96                                               2.46    1.09    6.13    1.23    0.949[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  MCP-1 (pg/mL)                         30                           106.3[f](#tfn9-vhrm-11-479){ref-type="table-fn"}                                             90.2       38.1    278.9   58.5    25   99.0[f](#tfn9-vhrm-11-479){ref-type="table-fn"}    95.4    30.7    223.4     52.7    24   140.5[f](#tfn9-vhrm-11-479){ref-type="table-fn"}   131.8   25.5    311.3   71.6    0.046[k](#tfn1-vhrm-11-479){ref-type="table-fn"}
  cIMT (mm)                             30                           0.62                                                                                         0.61       0.50    0.90    0.08    25   0.64                                               0.63    0.53    0.80      0.06    24   0.59                                               0.57    0.22    0.86    0.14    0.131[k](#tfn1-vhrm-11-479){ref-type="table-fn"}

**Notes:**

Kruskal-Wallis test;

Student's *t*-test for independent samples;

One-way analysis of variance, ANOVA;

Bonferroni-Dunn post hoc test, *P*=0.049;

Bonferroni-Dunn post hoc test, *P*=0.018;

Bonferroni-Dunn post hoc test, *P*=0.050;

Duncan post hoc test, *P*=0.016;

Duncan post hoc test, *P*=0.025;

Bonferroni-Dunn post hoc test did not detect any significant difference.

**Abbreviations:** ALL, acute lymphocytic leukemia; min, minimum value; max, maximum value; SD, standard deviation; BMI, body mass index; FMI, fat mass index; HOMA1-IR, homeostasis model assessment -- insulin resistance; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IGF-1, insulin-like growth factor-1; MCP-1, monocyte chemoattractant protein-1; cIMT, carotid intima-media thickness.

###### 

Summary measures of general characteristics, body composition and fat distribution, metabolic profile, blood pressure, and adipokine levels of ALL patients, according to sex

                                        Sex                                                                                          
  ------------------------------------- ----- ------- ------- ------- --------- ------- ---- ------- ------- ------- ------- ------- ---------------------------------------------------
  Age at assessment (years)             31    18.4    18.1    15.0    22.9      2.7     24   18.9    18.6    15.0    22.8    2.3     0.401[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  Time post-therapy (years)             31    8.5     8.0     4.0     16.4      3.5     24   8.5     8.4     2.5     14.3    3.5     0.968[t](#tfn12-vhrm-11-479){ref-type="table-fn"}
  BMI (Z score)                         31    0.15    0.26    −2.55   1.96      1.04    24   0.00    0.30    −2.88   2.14    1.36    0.665[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  FMI (kg/m^2^)                         31    7.8     7.3     3.2     15.5      2.8     24   5.2     4.3     1.8     11.8    3.1     0.001[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  Visceral adipose tissue (cm^3^)       31    99.3    81.3    24.0    250.9     59.1    24   124.7   100.6   21.9    265.3   69.2    0.149[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  Subcutaneous adipose tissue (cm^3^)   31    386.1   359.5   96.9    1,077.4   205.2   24   320.9   270.1   36.2    934.2   265.3   0.096[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  HOMA1-IR                              31    2.00    1.63    0.80    4.75      1.00    24   2.03    1.62    0.71    4.49    1.13    0.859[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  LDL-C (mmol/L)                        31    2.3     2.3     1.1     3.5       0.7     24   2.2     2.0     0.8     4.1     0.8     0.545[t](#tfn12-vhrm-11-479){ref-type="table-fn"}
  HDL-C (mmol/L)                        31    1.3     1.3     0.4     1.9       0.3     24   1.1     1.1     0.6     1.4     0.2     0.006[t](#tfn12-vhrm-11-479){ref-type="table-fn"}
  Triglycerides (mmol/L)                31    1.0     0.9     0.3     2.4       0.6     24   1.0     0.8     0.5     1.9     0.5     0.939[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  Systolic blood pressure (mmHg)        31    107.3   106.7   90.0    122.0     8.9     24   114.0   113.3   88.3    144.3   13.0    0.028[t](#tfn12-vhrm-11-479){ref-type="table-fn"}
  Diastolic blood pressure (mmHg)       31    68.4    66.7    56.7    80.0      5.8     24   73.1    70.0    56.7    100.0   10.9    0.151[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  IGF-1 (nmol/L)                        31    39.9    34.7    20.6    70.5      15.4    24   41.8    36.2    20.2    81.2    15.7    0.530[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  Leptin-to-adiponectin ratio (ng/µg)   31    2.92    2.35    1.16    9.11      1.90    24   3.85    3.27    1.58    8.02    1.88    0.011[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  MCP-1 (pg/mL)                         31    101.5   92.1    45.8    198.3     44.9    24   104.9   88.5    30.7    278.9   67.8    0.641[m](#tfn11-vhrm-11-479){ref-type="table-fn"}
  cIMT (mm)                             31    0.61    0.63    0.50    0.78      0.06    24   0.64    0.62    0.53    0.90    0.09    0.463[m](#tfn11-vhrm-11-479){ref-type="table-fn"}

**Notes:**

Mann-Whitney test;

Student's *t*-test for independent samples.

**Abbreviations:** ALL, acute lymphocytic leukemia; min, minimum value; max, maximum value; SD, standard deviation; BMI, body mass index; FMI, fat mass index; HOMA1-IR, homeostasis model assessment -- insulin resistance; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; IGF-1, insulin-like growth factor-1; MCP-1, monocyte chemoattractant protein-1; cIMT, carotid intima-media thickness.

###### 

Estimated parameters from multiple linear regression model, with the dependent variable being carotid intima-media thickness, among ALL patients

                                         Coefficient   Standard error (coefficient)   *t*      *P* value
  -------------------------------------- ------------- ------------------------------ -------- -----------
  (Constant)                             0.420640      0.077123                       5.454    \<0.001
  Exposure to CRT                        0.044374      0.019753                       2.246    0.029
  SAT (cm^3^)                            −0.000128     0.000045                       −2.830   0.007
  Diastolic blood pressure (mmHg)        0.0028815     0.001131                       2.488    0.016
  Leptin-to-adiponectin ratio (ng/mcg)   0.009745      0.004807                       2.027    0.048

**Abbreviations:** ALL, acute lymphocytic leukemia; CRT, cranial radiation therapy; SAT, subcutaneous adipose tissue.
